H2020Индивидуална стипендия2020–2022

MITO · The function and biomarker potential of mitochondrial microRNAs in hypertension

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2020-08-03 → 2022-08-02
Финансиране от ЕС: 178 320 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Митохондриалните микроРНК в кръвта се анализират чрез модел с машинно обучение за разпознаване на хипертония. Това помага за откриването на нови биомаркери, които да подобрят диагностиката и контрола на заболяването.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

The function and biomarker potential of mitochondrial microRNAs in hypertension

Hypertension is a complex disease resulting from dynamic interactions between genetic, lifestyle and environmental factors. Due to this multifaceted pathogenesis, aetiology of hypertension is unknown in 90-95% of patients. A significant proportion of patients are not aware that they have hypertension since this disease can remain silent for years without triggering any symptoms. Although it is straightforward to diagnose hypertension and relatively easy to treat the condition with low-cost drugs, recent hypertension prevalence data pinpointed that significant gaps in diagnosis and treatment remain. Thus, there is an unmet need for novel biomarkers for primordial prevention, better control, and decrease in morbidity and mortality associated with hypertension. Over the years, multiple candidate circulating protein-coding RNAs and noncoding RNAs (ncRNAs) have been identified in various hypertension phenotypes. Among them microRNAs (miRNAs), short ncRNA transcripts, appeared as attractive biomarkers for essential hypertension. Due to the fact that miRNAs participate in disease evolution and response to anti-hypertensive therapy, they represent promising diagnostic, prognostic and surrogate end-point biomarkers for follow-up of hypertension control. The main objective of the project was to discover clinically-translatable novel miRNA-based methods to improve healthcare of hypertensive patients. In line with that, the MITO project delivered a machine learning based model to predict essential hypertension using miRNA signature from whole blood. In addition, the project allowed a high-quality training of the MSCA fellow, covering three interlinked domains: biomarker discovery, biomarker validation and functional association. This training provided the MSCA fellow with with a strong knowledge of state-of-the-art technologies (WP1) which allowed to achieve the following scientific goals: (i) Discover novel circulating miRNAs associated with hypertension (WP2) – seven miRNAs and eight piwi-interacting RNAs (piRNAs) were identified as potential biomarkers for hypertension. (ii) Validate candidate miRNAs and explore gender differences (WP3) – the association with hypertension of six miRNAs was validated in a cohort of 572 participants. (iii) Determine functional associations between miRNAs and hypertension (WP4) - two lead miRNAs were selected for functional characterisation.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Hypertension is an extreme public health problem affecting nearly one third of the World’s adult population. Most cardiovascular diseases are provoked by hypertension resulting in an estimated 9.4 million deaths every year. Surprisingly, the diagnosis of hypertension has changed very little over the past 100 years - just using a stethoscope definitely needs refining. Furthermore, the epidemic proportion of hypertension worldwide pinpoints the necessity for the discovery of fresh antihypertensive therapies. Thus the main objective of the MITO project is to discover novel methods to improve healthcare of hypertension patients. For this we will investigate the circulating pool of microRNAs (small RNA molecules present in the blood, regulating gene expression) - we hypothesize that particularly mitochondrial microRNAs play a critical role in hypertension development. Easily obtainable in the blood, microRNAs constitute an accessible source of biomarkers and therapeutic targets for clinical application. The research plan envisages three scientific work packages dedicated (1) to the discovery of candidate microRNAs associated with hypertension by using small RNA sequencing in 30 hypertensive patients and 30 controls, (2) the validation of candidate microRNAs in a group of 540 participants (paying attention to sex specificities), and (3) to the functional assessment of the role of microRNAs in hypertension development. While the first two parts of the project will be conducted at the host institution in Luxembourg, functional studies will involve three secondments to partner institutions in Denmark, Germany, and France. A successful outcome will have implications ranging from contributing to satisfy the need for novel methods to stop the progression of hypertension, to a better understanding of the role of microRNAs in hypertension development, to the training of a young East European researcher to pioneer development in a research field just emerging in her home country.

Оригинален текст от CORDIS (на английски).

Участници

LUXEMBOURG INSTITUTE OF HEALTH · StrassenКоординаторЛюксембург